Volume Spike Investor

NeurogesX, Inc. (NASDAQ: NGSX) is an unknown stock to many, but it may become much more well known if this approval can be extended out to other uses.  The company yesterday after the close received FDA approval of its Qutenza, a new capsaicin prescription patch applied to the skin for one hour for reduction of post-shingles nerve pain.  Shares are up 11% at $9.21 and the 52-week range is $0.89 to $9.20.  We have already seen 71,000 shares trade hands and the average volume in this stock is a mere 67,000 shares.  Last night we saw a gain of almost 17% to $9.64 and there were 62,827 shares that traded in the after-hours session last night.

JON OGG